December 20th 2024
Jason M Pogue, PharmD, BCPS, BCIDP discusses the findings, pharmacokinetics, why ceftolozane-tazobactam may be the preferred choice for resistant infections, and more.
November 11th 2024
Market Pressures Hinder Access to Essential Antibiotics
June 20th 2017Commentary authors warn that lack of access to antibiotics to treat common bacterial infections are becoming difficult to access due to manufacturers finding them less profitable to produce and market; this can have serious implications.
Read More
Will Pennsylvania Proposal Sanction Improper Treatment of Lyme Disease?
June 16th 2017Amesh A. Adalja, MD, FIDSA argues that a bill being considered in the Pennsylvania state legislature will ultimately result in increased antibiotic resistance and will set back the clock for finding appropriate treatments for Lyme disease.
Read More
Why is Multidrug-Resistant Pseudomonas aeruginosa a Priority Pathogen?
June 13th 2017Jason Pogue, PharmD, BCPS-ID, Clinical Pharmacist, Infectious Diseases, Sinai-Grace Hospital, explains why Pseudomonas aeruginosa is one of the World Health Organization’s critical priority pathogens for new research and development priorities.
Watch